Immunexpress are delighted to announce that the study, “Validation of SeptiCyte® RAPID to Discriminate Sepsis from Non-Infectious Systemic Inflammation,” has been selected as an Editor’s Choice Paper for 2024 by the Journal of Clinical Medicine (JCM) MDPI Editorial Team. This honour underscores its importance in sepsis diagnostics and its clinical relevance.
This research provides critical validation of SeptiCyte RAPID in assessing sepsis probability and distinguishing sepsis from SIRS in critically ill adult patients. The findings support its effectiveness under both Sepsis-2 and Sepsis-3 frameworks, delivering actionable results within a clinically relevant time frame.
Read the journal article below.
Learn more about how SeptiCyte expands the possibilities of sepsis diagnosis.
* SeptiCyte RAPID is available for IVD use in Australia and New Zealand.
THESE PRODUCTS ARE NOT AVAILABLE FOR PURCHASE BY THE GENERAL PUBLIC.
